HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: CJN.03670807v1 3/2/505    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stenvinkel, P. Articles by Massy, Z. Search for Related Content PubMed PubMed Citation Articles by Stenvinkel, P. Articles by Massy, Z.

Emerging Biomarkers for Evaluating Cardiovascular Risk in the Chronic Kidney Disease Patient: How Do New Pieces Fit into the Uremic Puzzle?

Peter Stenvinkel^*, Juan Jesús Carrero^*, Jonas Axelsson^*, Bengt Lindholm^*, Olof Heimbürger^*, and Ziad Massy

^* Divisions of Renal Medicine and Baxter Novum, Department of Clinical Science, Intervention and Technology, Karolinska Institutet, Stockholm, Sweden; and INSERM, ERI-12, Amiens, France, and Division(s) of Clinical Pharmacology and Nephrology, University of Picardie and Amiens University Hospital, Amiens, France

Correspondence: Dr. Peter Stenvinkel, Department of Renal Medicine, K56, Karolinska University Hospital at Huddinge, 141 86 Stockholm, Sweden. Phone: +46-8-58582532; Fax: +46-8-7114742; E-mail: peter.stenvinkel{at}ki.se

Premature cardiovascular disease (CVD), including stroke, peripheral vascular disease, sudden death, coronary artery disease, and congestive heart failure, is a notorious problem in patients with chronic kidney disease (CKD). Because the presence of CVD is independently associated with kidney function decline, it appears that the relationship between CKD and CVD is reciprocal or bidirectional, and that it is this association that leads to the vicious circle contributing to premature death. As randomized, placebo-controlled trials have so far been disappointing and unable to show a survival benefit of various treatment strategies, such a lipid-lowering, increased dialysis dose and normalization of hemoglobin, the risk factor profile seems to be different in CKD compared with the general population. Indeed, seemingly paradoxical associations between traditional risk factors and cardiovascular outcome in patients with advanced CKD have complicated our efforts to identify the real cardiovascular culprits. This review focuses on the many new pieces that need to be fit into the complicated puzzle of uremic vascular disease, including persistent inflammation, endothelial dysfunction, oxidative stress, and vascular ossification. Each of these is not only highly prevalent in CKD but also more strongly linked to CVD in these patients than in the general population. However, a causal relationship between these new markers and CVD in CKD patients remains to be established. Finally, two novel disciplines, proteomics and epigenetics, will be discussed, because these tools may be helpful in the understanding of the discussed vascular risk factors.

This article has been cited by other articles:

				J. J. Carrero, X. Hua, P. Stenvinkel, A. R. Qureshi, O. Heimburger, P. Barany, B. Lindholm, and J. Frostegard Low levels of IgM antibodies against phosphorylcholine-A increase mortality risk in patients undergoing haemodialysis Nephrol. Dial. Transplant., November 1, 2009; 24(11): 3454 - 3460. [Abstract] [Full Text] [PDF]

				A. Takahashi, T. Shiga, M. Shoda, T. Manaka, K. Ejima, and N. Hagiwara Impact of renal dysfunction on appropriate therapy in implantable cardioverter defibrillator patients with non-ischaemic dilated cardiomyopathy Europace, November 1, 2009; 11(11): 1476 - 1482. [Abstract] [Full Text] [PDF]

				A. F. Perna, M. G. Luciano, D. Ingrosso, P. Pulzella, I. Sepe, D. Lanza, E. Violetti, R. Capasso, C. Lombardi, and N. G. De Santo Hydrogen sulphide-generating pathways in haemodialysis patients: a study on relevant metabolites and transcriptional regulation of genes encoding for key enzymes Nephrol. Dial. Transplant., August 4, 2009; (2009) gfp378v1. [Abstract] [Full Text] [PDF]

				A Power, N Duncan, and C Goodlad Management of the dialysis patient for the hospital physician Postgrad. Med. J., July 1, 2009; 85(1005): 376 - 381. [Abstract] [Full Text] [PDF]

				M. I. Yilmaz, J. Axelsson, A. Sonmez, J. J. Carrero, M. Saglam, T. Eyileten, K. Caglar, A. Kirkpantur, T. Celik, Y. Oguz, et al. Effect of Renin Angiotensin System Blockade on Pentraxin 3 Levels in Type-2 Diabetic Patients With Proteinuria Clin. J. Am. Soc. Nephrol., March 1, 2009; 4(3): 535 - 541. [Abstract] [Full Text] [PDF]

				J. J. Carrero, A. R. Qureshi, P. Parini, S. Arver, B. Lindholm, P. Barany, O. Heimburger, and P. Stenvinkel Low Serum Testosterone Increases Mortality Risk among Male Dialysis Patients J. Am. Soc. Nephrol., March 1, 2009; 20(3): 613 - 620. [Abstract] [Full Text] [PDF]

				J. Maizel, I. Six, M. Slama, C. Tribouilloy, H. Sevestre, S. Poirot, P. Giummelly, J. Atkinson, G. Choukroun, M. Andrejak, et al. Mechanisms of Aortic and Cardiac Dysfunction in Uremic Mice With Aortic Calcification Circulation, January 20, 2009; 119(2): 306 - 313. [Abstract] [Full Text] [PDF]

				J. J. Carrero, A. Ortiz, A. R. Qureshi, J. L. Martin-Ventura, P. Barany, O. Heimburger, B. Marron, G. Metry, S. Snaedal, B. Lindholm, et al. Additive Effects of Soluble TWEAK and Inflammation on Mortality in Hemodialysis Patients Clin. J. Am. Soc. Nephrol., January 1, 2009; 4(1): 110 - 118. [Abstract] [Full Text] [PDF]